• MAbSilico News

    MAbSilico presents its tools at the BIO Korea in partnership with Y-Biologics. May 2020

    MAbSilico is presenting its AI-driven solutions during the BIO Korea in May 2020 with its collaborator in South Korea Y-Biologics.
    BIO Korea is the Asia's Biggest Bio Convention, a substantive place of business with international information exchange, and technology transfer and has invigorated the bio industry for many years celebrating its 15th anniversary of leading Korean bio-industry’s future. Anne Poupon is presenting "Artificial Intelligence Methods for Therapeutic Antibodies Characterization" during the therapeutic antibody session.

    Join Us for this virtual presenation #antibody #drugdevelopment #insilico #AI

    MAbSilico and OSE Immunotherapeutics announce their collaboration. February 2020

    MAbSilico and OSE immnotherapeutics sign a collaboration for the use of artifical intelligence in antibody development. OSE Immunotherapeutics plans to incorporate innovative problem-solving solutions like AI for the development of new monoclonal antibodies. MAbSilico solutions have already been tested and validated by OSE Immunotherapeutics and will be used for six antibody programs, including novel bispecific antibodies. AI and numerical simulation can guide therapeutic antibody discovery, help reduce the risk of failure and accelerate the pre-clinical development process of these drug candidates before clinical tests.

    https://mailchi.mp/9c82fbfe8704/mabsilico-signs-a-collaboration-with-ose-immunotherapeutics

    MAbSilico awarded for a 1 M€ grant in the Bpifrance i-Nov competition. December 2019

    MAbSilico has just been attributed a grant of one million euros in the Bpifrance I-Nov competition. This rewards its software, which uses artificial intelligence and numeric simulation to guide therapeutic antibody discovery, reducing the risk of failure and the time during the development of these drug candidates before clinical tests. A revolution in the bio-drugs development process.

    https://mailchi.mp/d84d62a2f81e/mabsilico-awarded-for-a-1-m-grant-in-the-bpifrance-i-nov-competition?e=[UNIQID]

    MAbSilico presents its new tools at the 7th Antibody Industrial Symposium. June 2019

     

    The 7th Antibody Industrial Symposium (AIS2019) will be held the 24th and 25th of June 2019 in Tours, France. This congress, jointly organized by the scientific society LabEx MAbImprove and the industrial organization MabDesign, is part of the series of Industrial Symposia organized by MAbImprove since 2013 (Antibodies Biosimilars, MAbDosing, MAbDelivery, Current & Next Generation Antibody Formats, Antibody Drug Conjugates).

     

    Join Us at the #7AIS2019 Congress @congress_ais – 24/25 June – Tours FR. #innovativeapproaches #therapeuticAbs #mAbs #immunotherapy

    MAbSilico presents its tools at the 12th Annual Proteins & Antibodies Congress. April 2019

    At the annual Proteins & Antibodies Congress, MAbSilico will present the in silico tools with our partner Synthelis for antibody development among the best speakers from big pharma, biotechs, academia and technology innovators. Come to discuss about the most exciting breakthroughs for the discovery and development of antibodies..

     

    Come to visit us during our presentation session.

    MAbSilico is supporting the conference "Intelligence Artificielle & Développement des immunothérapies ". April 2019

    This event in Lyon gather the French companies and organization using Artificial Intelligence for the developpment of immunotherapies..

     

    Come to visit us at our booth.

    MAbSilico is happy to announce the release of the scientific paper "MAbTope" in the Journal of Immunoly. October 2018

    Discover our tools MAbTope and how this AI-driven solution can accelerate and secure the intellectual property of you antibodies. Based on the Ab sequence, perform quick and reliable epitope mapping.

     

    Read more about MAbTope.

    MAbSilico presents its technology at the European Antibody Congress. October 2018

    At the European Antibody Congress, MAbSilico will present the in silico methods for antibody development among the best speakers from big pharma, biotechs, academia and technology innovators to discuss the most exciting breakthroughs when it comes to the discovery and development of antibodies.

     

    Come to visit us at the booth or during the poster session.

    MAbSilico and Synthelis sign a commercial agreement to promote a joint service offering. June 2018

    As of June 21, 2018, Synthelis and MAbSilico combine their know-how and thus capitalize on their respective technology in developing a joint offer through a commercial agreement, responding to the needs of their customers.

     

    This offer combines the cutting-edge expertise of two recognized players in their respective domain: MAbSilico with its in silico method to characterize antibodies at their early stage of development and Synthelis, for its cell-free patented technology.

    MAbSilico is talking at the 6th Antibody Industrial Symposium. June 2018

    The 6th Antibody Industrial Symposium 2018 (AIS2018) will be held the 25th and 26th of June 2018 in Montpellier, France. This congress, jointly organized by the scientific society LabEx MAbImprove and the industrial organization MabDesign, is part of the series of Industrial Symposia organized by MAbImprove since 2013 (Antibodies Biosimilars, MAbDosing, MAbDelivery, Current & Next Generation Antibody Formats, Antibody Drug Conjugates).

    MAbSilico is selected to be accelerated at Le Château. March 2018

    Le Château is an accelerating program for early stage startups.

    MAbSilico is talking at the Immunotherapies for Infectious Diseases Congress. December 2017

    The second edition of the Immunotherapies for Infectious Diseases Congress - I4ID, that will be held in Lyon (France) on December 10-11, 2018, this year dedicated to Host-Directed Therapies (HDT) to fight infectious diseases.

    MAbSilico is selected in the top 500 startups at the Hello Tomorrow Global Challenge. October 2017

    The Hello Tomorrow Challenge is the world’s biggest early-stage startup competition for science and deep technology startups. Each year, they identify the best projects of the Challenge to attend the Hello Tomorrow Summit in Paris, an invite-only event bringing together the people that will change the world using science and technology around top investors in each sector, industrial leaders (Airbus, Google[x], Carrefour, Merck, Air Liquide, Facebook, etc.), international media (Bloomberg, BBC, Wired, etc.) and influencers (in 2016, Mike Bloomberg, Emmanuel Macron, CTO of Meta, CEO of Unity Biotech, etc).

    MAbSilico is at the Next-Generation Antibodies and Protein Analysis. October 2017

    Catalyzed by VIB’s Technology Scouting team, the Tools and Technologies meetings focus on the front end of innovation and bring together key innovators in selected life sciences research fields. The Next-Generation Antibodies and Protein Analysis conference, in Ghent (Belgium), is set to make another world class meeting, bringing together an exciting selection of top speakers and newly emerged companies. In addition to great scientific and technology program, the conference will provide ample networking opportunities.

    MAbSilico received the "Bourse French Tech" from Bpifrance. October 2017

    MAbSilico is founded. September 2017

    We are happy to announce the incorporation of MAbSilico.